Proto Labs Reports Exit Costs & Impairments
Ticker: PRLB · Form: 8-K · Filed: Oct 25, 2024 · CIK: 1443669
| Field | Detail |
|---|---|
| Company | Proto Labs Inc (PRLB) |
| Form Type | 8-K |
| Filed Date | Oct 25, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001, $4.5 million, $6.0 m, $2.5 million, $3.5 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: impairment, restructuring, disposal
Related Tickers: PRLB
TL;DR
Proto Labs is taking a hit on exit costs and impairments, expect financial shifts.
AI Summary
Proto Labs, Inc. filed an 8-K on October 25, 2024, reporting material impairments and costs associated with exit or disposal activities as of October 21, 2024. The filing indicates significant financial events related to restructuring or asset disposals, though specific dollar amounts and details of these activities are not provided in this excerpt.
Why It Matters
This filing signals potential financial restructuring or asset sales by Proto Labs, which could impact its future operational capacity and financial performance.
Risk Assessment
Risk Level: medium — The filing indicates material impairments and exit costs, suggesting potential financial distress or significant strategic changes that could affect the company's value.
Key Numbers
- 001-35435 — SEC File Number (Identifies the company's filing with the SEC.)
- 41-1939628 — IRS Employer Identification Number (Company's tax identification number.)
Key Players & Entities
- Proto Labs, Inc. (company) — Registrant
- October 21, 2024 (date) — Earliest event reported
- October 25, 2024 (date) — Filing date
- 5540 Pioneer Creek Drive (address) — Principal executive offices
- Maple Plain, Minnesota 55359 (address) — Principal executive offices
FAQ
What specific assets or operations are subject to the reported exit or disposal activities?
The provided excerpt does not specify which assets or operations are involved in the exit or disposal activities.
What is the estimated financial impact of the material impairments?
The filing excerpt does not provide specific dollar amounts for the material impairments.
What is the nature of the costs associated with the exit or disposal activities?
The filing excerpt mentions costs associated with exit or disposal activities but does not detail their nature.
When did the events triggering these disclosures occur?
The earliest event reported occurred on October 21, 2024.
Is Proto Labs undergoing a significant restructuring or divestiture?
The reporting of material impairments and exit/disposal costs suggests potential restructuring or divestiture, but the filing excerpt does not explicitly confirm this.
Filing Stats: 802 words · 3 min read · ~3 pages · Grade level 11.9 · Accepted 2024-10-25 06:11:03
Key Financial Figures
- $0.001 — ich registered Common Stock, Par Value $0.001 Per Share PRLB New York Stock Exchange
- $4.5 million — l restructuring charges in the range of $4.5 million to $6.0 million, consisting of approxim
- $6.0 m — charges in the range of $4.5 million to $6.0 million, consisting of approximately $2.5
- $2.5 million — .0 million, consisting of approximately $2.5 million to $3.5 million in severance and other
- $3.5 million — isting of approximately $2.5 million to $3.5 million in severance and other employee-related
- $2.0 million — e and other employee-related costs, and $2.0 million to $2.5 million in fixed asset and faci
- $4.0 million — company expects to incur approximately $4.0 million of the total restructuring charge in th
- $3.0 million — plan are expected to be in the range of $3.0 million to $4.0 million, consisting primarily o
- $4.0 m — d to be in the range of $3.0 million to $4.0 million, consisting primarily of severanc
Filing Documents
- prlb-20241021.htm (8-K) — 29KB
- 0001628280-24-043734.txt ( ) — 149KB
- prlb-20241021.xsd (EX-101.SCH) — 2KB
- prlb-20241021_lab.xml (EX-101.LAB) — 21KB
- prlb-20241021_pre.xml (EX-101.PRE) — 12KB
- prlb-20241021_htm.xml (XML) — 3KB
05. Costs Associated with Exit or Disposal Activities
Item 2.05. Costs Associated with Exit or Disposal Activities. On October 21, 2024, the Board of Directors of Proto Labs, Inc. (the "Company") approved a plan related to the Company's manufacturing facilities in Germany. The plan includes the closure of the Company's prototype injection molding manufacturing facility in Eschenlohe, Germany, and the discontinuation of Direct Metal Laser Sintering 3D printing services through its 3D printing facility in Putzbrunn, Germany. Affected employees in Germany will receive severance and other transition assistance that meet or exceed local requirements. The Company expects to substantially complete the plan within the next year. The Company will continue offering all its manufacturing services to customers across Europe, including injection molding and metal 3D printing. These services will be fulfilled through internal manufacturing facilities and a network of manufacturing partners, consistent with the Company's recently announced global operations organization. The approved plan is expected to lead to total restructuring charges in the range of $4.5 million to $6.0 million, consisting of approximately $2.5 million to $3.5 million in severance and other employee-related costs, and $2.0 million to $2.5 million in fixed asset and facility related write-down expenses. The company expects to incur approximately $4.0 million of the total restructuring charge in the fourth quarter of 2024, with the remaining charge to be incurred throughout the remainder of the restructuring process. The total cash expenditures associated with the plan are expected to be in the range of $3.0 million to $4.0 million, consisting primarily of severance and other employee related costs.
06. Material Impairments
Item 2.06. Material Impairments. To the extent required, the information contained in Item 2.05 of this Current Report on Form 8-K is incorporated by reference herein.
Forward-Looking Statements
Forward-Looking Statements SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Proto Labs, Inc. Date: October 25, 2024 By: /s/ Robert Bodor Robert Bodor President and Chief Executive Officer